Kornitzer Capital Management Inc. KS Sells 31,000 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Kornitzer Capital Management Inc. KS lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,262 shares of the medical research company’s stock after selling 31,000 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in IQVIA were worth $13,021,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of IQV. Smith Group Asset Management LLC purchased a new stake in IQVIA during the 4th quarter worth about $1,616,000. Simplify Asset Management Inc. boosted its position in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the period. Nordea Investment Management AB grew its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Fifth Third Bancorp lifted its stake in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS boosted its holdings in IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after purchasing an additional 2,700 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $193.65 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $35.15 billion, a P/E ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48. The business’s 50 day moving average price is $200.41 and its 200-day moving average price is $217.82. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Leerink Partners restated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.